ClinicalTrials.gg
CompletedNCT05543174Updated Jan 29, 2026Results posted

A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)

A Phase 3 interventional study of TAK-625 in Alagille Syndrome (ALGS), sponsored by Takeda. Completed at 8 sites in Japan. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
1 Month and older
Sex
All
01

Study summary

The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.

The participants will be treated with TAK-625 for up to the end of study (about 34 months).

Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.

02

Conditions studied

  • Alagille Syndrome (ALGS)

Browse trials for

03

In context

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

This study's enrollment of 7 is below the median of 31 across 15 interventional studies indexed under Alagille Syndrome.

Browse Alagille Syndrome studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is Japanese male or female with a body weight >=3.0 kilograms (kg) and who is >=1 month of age at the time of .
  2. The participant is diagnosed with ALGS.
  3. The participant has one or more of the following evidences of cholestasis:

    1. Total serum bile acid (sBA) >3\^ (ULN) for age.
    2. Direct (conjugated) >1 mg/dL.
    3. Lipid soluble vitamin (LSV) deficiency otherwise unexplainable.
    4. Gamma-glutamyl transferase (GGT) >3\^ ULN for age.
    5. Intractable pruritus explainable only by liver disease.
  4. The participant is expected to have a consistent caregiver(s) for the duration of the study.
  5. The participant has an access to phone for scheduled calls from study site.
  6. Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
  7. Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
  8. Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the participant is an adult (over 18 years old).
  9. Average daily score >2 on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, participants \<12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.

Exclusion criteria

Exclusion Criteria:

  1. The participant has chronic diarrhea requiring ongoing intravenous (IV) fluid or nutritional intervention.
  2. The participant has a previous history of surgical interruption of the enterohepatic circulation.
  3. The participant has a previous liver transplant.
  4. The participant decompensated cirrhosis ( >15\^ , [INR] >1.5 [unresponsive to vitamin K therapy], albumin \<3.0 g/dL, history or presence of ascites, variceal hemorrhage, and/or encephalopathy).
  5. The participant has a history or presence of other concomitant liver disease.
  6. The participant has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
  7. The participant has a history or presence of gallstones or kidney stones.
  8. The participant has a possible malignant liver mass in imaging, including screening ultrasound.
  9. The participant has cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
  10. The participant has received bile acid/lipid binding resins or IBAT inhibitors within 28 days prior to screening and throughout the trial.
  11. The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    TAK-625

    TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.

    Drug: TAK-625

Interventions

  • TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily

    Also known as: Maralixibat chloride

06

What researchers measure

Primary outcomes

  1. Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22

    Change in fasting sBA levels from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22- observed value at Week 18.

    Time frame: From Week 18 to Week 22

Secondary outcomes

  1. Change in Fasting sBA Levels From Baseline to Week 18

    Change in fasting sBA levels from baseline to Week 18 was reported. Change was calculated as: observed value at Week 18 - observed value at baseline (before dosing).

    Time frame: Baseline to Week 18

  2. Change in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18

    The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity of Pruritus is calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Obs). Weekly average severity was calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

    Time frame: Baseline to Week 18

  3. Change in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18

    The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

    Time frame: Baseline to Week 18

  4. Change in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22

    The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity of Pruritus was calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Obs). Weekly average severity were calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

    Time frame: From Week 18 to Week 22

  5. Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22

    The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

    Time frame: From Week 18 to Week 22

  6. Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18

    The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average severity of Pruritus was calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Pt). Weekly average scores was calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

    Time frame: Baseline to Week 18

  7. Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18

    The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

    Time frame: Baseline to Week 18

  8. Change in Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels From Baseline to Week 18

    Change in ALT and ALP levels from baseline to Week 18 were reported. Change was calculated as: observed value at Week 18 - observed value at baseline (before dosing).

    Time frame: Baseline to Week 18

  9. Change in Bilirubin (Total and Direct) Levels From Baseline to Week 18

    Change in bilirubin (total and direct) from baseline to Week 18 was reported. Change was calculated as: observed value at Week 18 - observed value at baseline (before dosing).

    Time frame: Baseline to Week 18

  10. Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22

    The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average severity of Pruritus was calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Pt). Weekly average scores was calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

    Time frame: From Week 18 to 22

  11. Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22

    The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

    Time frame: From Week 18 to 22

  12. Change in ALT and ALP Levels From Week 18 to 22

    Change in ALT and ALP from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22 - observed value at Week 18.

    Time frame: From Week 18 to 22

  13. Change in Bilirubin (Total and Direct) Levels From Week 18 to 22

    Change in bilirubin (total and direct) from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22 - observed value at Week 18.

    Time frame: From Week 18 to 22

07

Results

Posted Oct 15, 2024

Participant flow

Participants took part in the study at 8 sites in Japan.

Participant flow — Overall Study
MilestoneTAK-625
Started7
Dosed tak-625 200 mcg/kg7
Dosed tak-625 400 mcg/kg7
Completed6
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22

Change in fasting sBA levels from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22- observed value at Week 18.

Time frame:
From Week 18 to Week 22
Reported as:
Mean · micromoles per liter (mcmol/L)
Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22
micromoles per liter (mcmol/L)TAK-625
Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 2217.643 (-31.6389 to 66.9246)
SecondaryChange in Fasting sBA Levels From Baseline to Week 18

Change in fasting sBA levels from baseline to Week 18 was reported. Change was calculated as: observed value at Week 18 - observed value at baseline (before dosing).

Time frame:
Baseline to Week 18
Reported as:
Mean · mcmol/L
Change in Fasting sBA Levels From Baseline to Week 18
mcmol/LTAK-625
Change in Fasting sBA Levels From Baseline to Week 188.300 (-37.4110 to 54.0110)
SecondaryChange in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18

The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity of Pruritus is calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Obs). Weekly average severity was calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

Time frame:
Baseline to Week 18
Reported as:
Mean · score on a scale
Change in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18
score on a scaleTAK-625
Change in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18-1.531 (-2.3405 to -0.7208)
SecondaryChange in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18

The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

Time frame:
Baseline to Week 18
Reported as:
Mean · score on a scale
Change in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18
score on a scaleTAK-625
Change in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18-1.327 (-2.1071 to -0.5460)
SecondaryChange in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22

The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average severity of Pruritus was calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Obs). Weekly average severity were calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

Time frame:
From Week 18 to Week 22
Reported as:
Mean · score on a scale
Change in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22
score on a scaleTAK-625
Change in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22-0.286 (-0.6594 to 0.0880)
SecondaryChange in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22

The ItchRO (Obs) scale measures severity of pruritus. The score on ItchRO (Obs) scale ranged from 0 to 4, where 0=None observed or reported, 1=Mild, 2=Moderate, 3=Severe, 4=Very severe. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

Time frame:
From Week 18 to Week 22
Reported as:
Mean · score on a scale
Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22
score on a scaleTAK-625
Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22-0.280 (-0.6769 to 0.1163)
SecondaryChange in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18

The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average severity of Pruritus was calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Pt). Weekly average scores was calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

Time frame:
Baseline to Week 18
Reported as:
Mean · score on a scale
Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18
score on a scaleTAK-625
Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18-1.381 (-5.0058 to 2.2439)
SecondaryChange in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18

The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 18 (Day 120 to Day 126) - average value of baseline (Day -7 to Day -1).

Time frame:
Baseline to Week 18
Reported as:
Mean · score on a scale
Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18
score on a scaleTAK-625
Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18-1.238 (-3.6537 to 1.1775)
SecondaryChange in Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels From Baseline to Week 18

Change in ALT and ALP levels from baseline to Week 18 were reported. Change was calculated as: observed value at Week 18 - observed value at baseline (before dosing).

Time frame:
Baseline to Week 18
Reported as:
Mean · Units per liter (U/L)
Change in Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels From Baseline to Week 18
Units per liter (U/L)TAK-625
Change in ALT17.7 (-52.66 to 88.09)
Change in ALP75.6 (-186.50 to 337.64)
SecondaryChange in Bilirubin (Total and Direct) Levels From Baseline to Week 18

Change in bilirubin (total and direct) from baseline to Week 18 was reported. Change was calculated as: observed value at Week 18 - observed value at baseline (before dosing).

Time frame:
Baseline to Week 18
Reported as:
Mean · mcmol/L
Change in Bilirubin (Total and Direct) Levels From Baseline to Week 18
mcmol/LTAK-625
Change in total bilirubin11.3619 (-20.13472 to 42.85861)
Change in direct bilirubin8.6009 (-15.59872 to 32.80046)
SecondaryChange in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22

The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average severity of Pruritus was calculated based on daily maximum of morning and evening severity scores measured by ItchRO (Pt). Weekly average scores was calculated as the average of the daily maximum of morning and evening over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

Time frame:
From Week 18 to 22
Reported as:
Mean · score on a scale
Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22
score on a scaleTAK-625
Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 220.000 (-0.6147 to 0.6147)
SecondaryChange in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22

The ItchRO (Pt) scale measures severity of pruritus. The score on ItchRO (Pt) scale ranged from 0 to 4, where 0= Not felt itchy, 1= Felt a little bit itchy, 2= Felt pretty itchy, 3= Felt very itchy, 4= Felt very, very itchy. A higher score indicated more severe pruritus. Weekly average morning severity was calculated as the average of the daily morning scores over the visit consisting of the 7 days on or before the scheduled Study Day (i.e., the sum of the scores divided by the number of non-missing scores). Change was calculated as: average value of Week 22 (Day 148 to Day 154) - average value of Week 18 (Day 120 to Day 126).

Time frame:
From Week 18 to 22
Reported as:
Mean · score on a scale
Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22
score on a scaleTAK-625
Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22-0.032 (-0.4120 to 0.3485)
SecondaryChange in ALT and ALP Levels From Week 18 to 22

Change in ALT and ALP from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22 - observed value at Week 18.

Time frame:
From Week 18 to 22
Reported as:
Mean · U/L
Change in ALT and ALP Levels From Week 18 to 22
U/LTAK-625
Change in ALT7.9 (-22.18 to 37.89)
Change in ALP-32.3 (-79.12 to 14.55)
SecondaryChange in Bilirubin (Total and Direct) Levels From Week 18 to 22

Change in bilirubin (total and direct) from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22 - observed value at Week 18.

Time frame:
From Week 18 to 22
Reported as:
Mean · mcmol/L
Change in Bilirubin (Total and Direct) Levels From Week 18 to 22
mcmol/LTAK-625
Change in total bilirubin0.6842 (-4.60580 to 5.97412)
Change in direct bilirubin1.2217 (-1.83803 to 4.28146)

Adverse events

Collected over From the first dose of study drug up to Week 133. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAK-6250/7 (0%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventTAK-625
Liver transplantSurgical and medical procedures1/7
MalnutritionMetabolism and nutrition disorders1/7
Weight gain poorMetabolism and nutrition disorders1/7
Most frequent other events
Showing 10 of 31
Most frequent other events
EventTAK-625
InfluenzaInfections and infestations4/7
Upper respiratory tract infectionInfections and infestations3/7
Alanine aminotransferase increasedInvestigations2/7
Dermatitis atopicSkin and subcutaneous tissue disorders2/7
Dermatitis diaperSkin and subcutaneous tissue disorders2/7
Hand-foot-and-mouth diseaseInfections and infestations2/7
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders2/7
Administration site extravasationGeneral disorders1/7
AnaemiaBlood and lymphatic system disorders1/7
Anal rashGastrointestinal disorders1/7

Baseline characteristics

Intention-to-treat (ITT) included all participants who received at least one dose of study drug. As per-planned analysis, the data for baseline measures were collected, analyzed and reported as a single cohort.

Age, Continuous
Age, Continuous(years)TAK-625
Mean6.143 ± 3.8675
Sex: Female, Male
Sex: Female, Male(Participants)TAK-625
Female2
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TAK-625
Asian7
08

Study locations

8 sites
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki, Japan
  • Yokohamashi Tobu Hospital
    Yokohama, Kanagawa, Japan
  • Miyagi Children's Hospital
    Sendai, Miyagi, Japan
  • Kindai University Nara Hospital
    Ikoma, Nara, Japan
  • Osaka University Hospital
    Suita, Osaka, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo, Japan
  • Kyoto University Hospital
    Kyoto, Japan
  • Saitama Prefectural Children's Medical Center
    Saitama, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Oct 2023, 9 months.

Results were first posted in Oct 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Sep 16, 2022
StartActual
Jan 16, 2023
Primary completionActual
Oct 25, 2023
CompletionActual
Jul 25, 2025
Results first posted
Oct 15, 2024
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05543174
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 16, 2022
Start date
Jan 16, 2023
Primary completion
Oct 25, 2023
Completion
Jul 25, 2025
Results posted
Oct 15, 2024
Last update
Jan 29, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion